Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

755.00 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Mid-Year Momentum Plays: 7 Stocks to Buy for the Second Half
Although going with the crowd comes with a certain comfort level, daring investors may want to consider these less-discussed momentum stocks. 
Via InvestorPlace
Growth Stock Goliaths: 7 Picks That Will Tower Over the Competition
Investors who want to put some sizzle in their portfolios should consider investing in these growth names that offer big returns. 
Via InvestorPlace
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Via Benzinga
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy
NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new avenues for long-term treatment. 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $700 Today
Via Benzinga
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Google Parent Alphabet Appoints Eli Lilly's Finance Chief Ashkenazi As CFO
Anat Ashkenazi resigns as CFO of Eli Lilly to join Google as CFO and SVP. She will remain at Lilly until July 2024 while her successor is sought. 
Via Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. 
Via Investor's Business Daily
Alphabet Picks Eli Lilly Executive Anat Ashkenazi As New CFO
Google stock rose after Alphabet announced that its new CFO will be Anat Ashkenazi, currently an executive at drug maker Eli Lilly. 
Via Investor's Business Daily
AMZN Buy Alert: Why Amazon Stock Is a Bargain Hiding in Plain Sight
The valuation of Amazon stock is quite low while multiple, large investors bought significant amounts of the shares in Q1. 
Via InvestorPlace
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Performance Comparison: Eli Lilly and Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target 
Via Benzinga
Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
QurAlis has entered an exclusive license agreement with Eli Lilly for QRL-204, an antisense oligonucleotide for ALS and other neurodegenerative diseases. QurAlis will receive $45 million upfront, with... 
Via Benzinga
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
The fight for dominance in the weight loss market is just getting started. 
Via The Motley Fool
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments 
Via MarketBeat
4 Stocks Making New Highs Despite Market Weakness
While the market faced challenges on Friday, Birkenstock, NetApp, Eli Lilly, and Aflac showed notable strength by achieving new 52-week highs. 
Via MarketBeat
The Week Ahead: What's Next
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
These two drugmakers have a lot more in common than their market-beating potential. 
Via The Motley Fool
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
These stocks are trading at sky-high valuations which could make them vulnerable to sell-offs. 
Via The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes
Novo Nordisk has filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling impure or falsely labeled semaglutide products. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
Sometimes the next big thing stocks to buy and hold are flying well under the radar. Here are three to consider. 
Via InvestorPlace
Aristocrats in Disguise: 3 Blue-Chip Stocks With Stealth Growth Potential
These blue-chip growth stocks provide the cornerstone for building a portfolio offerings a wealth of lucrative returns for years. 
Via InvestorPlace
Institutional Bets: 7 Stocks the Big Money Will Send Higher This Year
Institutions exert a powerful influence over these institutional favorite stocks that individual investors can benefit from in 2024. 
Via InvestorPlace
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks. 
Via Benzinga
Topics ETFs
Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs
Goldman Sachs re-rated Eli Lilly and Novo Nordisk, citing potential for weight-loss drugs. Global sales expected to reach $130B by 2030. 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.